Topics
Diffuse midline glioma | Treatment | Immunotherapy | CAR-T cells
Home > Publications > Topics > Diffuse midline glioma > Treatment > Immunotherapy > CAR-T cells
*Monje
M, Mahdi J, Majzner R, Yeom K, Schultz LM, Richards RM, Barsan V,
Song KW, Kamens J, Baggott C, Kunicki M, Lim AS, Reschke A,
Mavroukakis S, Egeler E, Moon J, Patel S, Chinnasamy H, Erickson
C, Jacobs A, Duh AK, Rietberg SP, Tunuguntla R, Klysz DD, Fowler
C, Green S, Beebe B, Carr C, Fujimoto M, Brown AK, Petersen AG,
McIntyre C, Siddiqui A, Lepori-Bui N, Villar K, Pham K, Bove R,
Musa E, Reynolds W, Kuo A, Prabhu S, Rasmussen L, Cornell TT,
Partap S, Fisher PG, Campen CJ, Grant G, Prolo L, Ye X, Sahaf B,
Davis KL, Feldman SA, Ramakrishna S, Mackall C.
Sequential
intravenous and intracerebroventricular GD2-CAR T-cell therapy for
H3K27M-mutated diffuse midline gliomas.
medRxiv
[Preprint].
2024 Jun 27:2024.06.25.24309146. doi:
10.1101/2024.06.25.24309146. PMID:
38978673. Interventional study. ˍ
*Ledford H.
This kids' brain cancer is
incurable - but immune therapy holds
promise.
Nature.
2024 Jul 12. doi:
10.1038/d41586-024-02255-2. PMID:
38997564. News. ˍ
Power
EA, Millesi E, Rechberger JS, Daniels DJ.
CAR-T
cells for H3K27-altered diffuse midline gliomas: where do we
stand?
Immunotherapy.
2024 Jul 17:1-4. doi:
10.1080/1750743X.2024.2373043. PMID:
39016046. Editorial˰ ˍ